

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

1. **(Amended)** A safe for injection, low volume formulation of dantrolene sodium, ~~or salts or analogues thereof~~, for administration to mammals, comprising:

~~a medicament which includes~~ dantrolene sodium at a concentration in the range of 30 - 80 mg/ml or in the range of 10 – 60 mg/ml; ~~or one or more salts or analogues thereof;~~

a water-soluble polysorbate;

a compound selected from the group consisting of sorbitol and mannitol; and

water as a liquid carrier, said medicament being dissolved or dispersed in said liquid carrier, said medicament being present in a concentration wherein 3 to 150 milliliters of liquid carrier provides approximately 500 milligrams of medicament,

wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.

2. (Withdrawn; **Canceled**)

3. **(Amended)** The safe for injection, low volume formulation of claim 1, wherein ~~said medicament includes dantrolene in its salt form wherein a counterion to a dantrolene anion is selected from the group consisting of potassium, sodium, ammonium, calcium and magnesium~~ the formulation consists essentially of:

dantrolene sodium at a concentration in the range of 30 - 80 mg/ml or in the range of 10 – 60 mg/ml;

a water-soluble polysorbate;

a compound selected from the group consisting of sorbitol and mannitol; and

water as a liquid carrier,

wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.

4. (Withdrawn; **Canceled**)

5. (**Amended**) The safe for injection low volume formulation of claim 1, wherein the dantrolene sodium ~~or one or more salts or analogues thereof~~ is the primary modulator of intracellular calcium present in said ~~medicament~~ the formulation.

6. (**Canceled**)

7. (**Canceled**).

8. (**Canceled**).

9. (**Canceled**)

10. (**Canceled**)

11. (**Canceled**)

12. (**Amended**) The safe for injection, low volume formulation of claim 1, further comprising a ~~stabilizer~~ polyvinylpyrrolidone (PVP).

13. (**Amended**) The safe for injection, low volume formulation of claim 4 12, consisting essentially of: ~~wherein said medicament and said liquid carrier are present together in a solution~~
dantrolene sodium at a concentration in the range of 30 - 80 mg/ml or in the range of 10 – 60 mg/ml;

a water-soluble polysorbate;
a compound selected from the group consisting of sorbitol and mannitol;
polyvinylpyrrolidone (PVP); and
water as a liquid carrier,
wherein said dantrolene sodium and water are present together as a colloidal dispersion
of dantrolene sodium particles in the water,
wherein the dantrolene sodium particles are less than about 2 microns in average
diameter, and
wherein the formulation is safe for intravenous administration.

.

14. **(Canceled)**

15. (Withdrawn; **Canceled**)

16. (Withdrawn; **Canceled**)

17. (Withdrawn; **Canceled**)

18. **(Canceled)**

19. **(Amended)** The safe for injection, low volume formulation of claim 1, wherein at least 95% of the dantrolene sodium particles ~~of medicament~~ in said liquid carrier are no more than 0.8 microns in diameter.

20. **(Amended)** The safe for injection, low volume formulation of claim 1, wherein at least 95% of the dantrolene sodium particles ~~of medicament~~ in said liquid carrier are no more than 0.45 microns in diameter.

21. **(Amended)** The safe for injection, low volume formulation of claim 1, wherein no particles of dantrolene sodium ~~medicament~~ in said liquid carrier are more than 2 microns in diameter.

22. (**Amended**) The safe for injection, low volume formulation of claim 1, wherein the compound is mannitol and the formulation comprises ~~comprising~~ no more than 30 milligrams of mannitol per milligram of dantrolene.

23. (**Canceled**)

24. (**Canceled**)

25. (**Canceled**)

26. (**Canceled**)

27. (Withdrawn; **Canceled**)

28. (Withdrawn; **Canceled**)

29. (Withdrawn **Canceled**)

30-74. (Canceled)

75. (Withdrawn; **Canceled**)

76. (Withdrawn; **Canceled**)

77. (Withdrawn; **Canceled**)

78. (Withdrawn; **Canceled**)

79-80. (Canceled)

81. (Withdrawn; **Canceled**)

82. (Canceled)

83. (**Canceled**)

84. (**Canceled**)

85. (**Amended**) The composition of claim 1, ~~83~~ wherein said water soluble polysorbate surfactant has a solubility of 5 mg/ml or greater.

86. (**Amended**) The composition of claim 1, ~~83~~ further comprising a ~~second~~ medicament different from said dantrolene ~~or salt of dantrolene medicament~~ sodium.

87. (**Canceled**)

88. (**Amended**) The composition of claim 1, ~~83~~ further comprising a quantity of liquid which permits administration of a therapeutic dose of dantrolene by injection of said composition to a patient.

89. (Previously presented) The composition of claim 88 wherein said quantity ranges from 3 - 150 milliliters.

90. (Previously presented) The composition of claim 88 wherein said quantity is 10 milliliters or less.

91. (Previously presented) The composition of claim 88 wherein said quantity is 5 milliliters or less.

92. (Canceled)

93. **(Canceled)**

94. **(Canceled)**

95. (Canceled)

96. **(Canceled)**

97. **(Canceled)**

98. **(Canceled)**

99. **(Canceled)**

100. **(Canceled)**

101. **(Canceled)**

102. **(Canceled)**

103. **(Canceled)**

104. **(Canceled)**

105. **(Canceled)**

106. (Previously presented) The safe for injection, low volume formulation of claim 1 comprising a dose of 250 - 300mg dantrolene sodium and which can be safely administered to a human by a single bolus injection in less than one minute.

107. (Previously presented) The safe for injection, low volume formulation of claim 106 comprising a dose of 250 mg of dantrolene sodium.

108. **(Canceled)**

109. **(Canceled)**

110. **(Amended)** The safe for injection, low volume formulation of claim 1, wherein said dantrolene sodium ~~medicament~~ is present at 50 mg/ml.

111. **(Canceled)**

112. **(Canceled)**

113. **(Canceled)**

114. **(Canceled)**

115. **(Canceled)**

116. **(Canceled)**

117. **(New)** A safe for injection, low volume liquid formulation of dantrolene sodium for administration to mammals, comprising:

dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene;
a water-soluble polysorbate;
a compound selected from the group consisting of sorbitol and mannitol; and
water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,
wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and
wherein the formulation is safe for intravenous administration.

118. **(New)** The safe for injection, low volume liquid formulation of dantrolene sodium of claim 117, consisting essentially of:

dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene;
a water-soluble polysorbate;
a compound selected from the group consisting of sorbitol and mannitol; and
water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,
wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and
wherein the formulation is safe for intravenous administration.

119. **(New)** The safe for injection, low volume liquid formulation of dantrolene sodium of claim 117, consisting essentially of:

dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene;
a water-soluble polysorbate;
a compound selected from the group consisting of sorbitol and mannitol;
polyvinylpyrrolidone (PVP); and
water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,
wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and
wherein the formulation is safe for intravenous administration.